These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35965583)

  • 1. Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors.
    Gu Y; Wei C; Chung M; Li H; Guo Z; Long M; Li Y; Wang W; Aimaier R; Li Q; Wang Z
    Front Oncol; 2022; 12():910505. PubMed ID: 35965583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Calizo A; Pratilas CA
    Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response.
    Gu Y; Wang W; Li Y; Li H; Guo Z; Wei C; Long M; Chung M; Aimaier R; Li Q; Wang Z
    Front Oncol; 2022; 12():903177. PubMed ID: 35875109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.
    Fischer-Huchzermeyer S; Chikobava L; Stahn V; Zangarini M; Berry P; Veal GJ; Senner V; Mautner VF; Harder A
    BMC Res Notes; 2018 Jul; 11(1):520. PubMed ID: 30055648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.
    Fischer-Huchzermeyer S; Dombrowski A; Wilke G; Stahn V; Streubel A; Mautner VF; Harder A
    PLoS One; 2017; 12(11):e0187700. PubMed ID: 29131833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors.
    Landers SM; Bhalla AD; Ma X; Lusby K; Ingram D; Al Sannaa G; Wang WL; Lazar AJ; Torres KE
    J Cancer Sci Clin Ther; 2020; 4(4):511-525. PubMed ID: 33283192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I.
    Wang W; Cui XW; Gu YH; Wei CJ; Li YH; Ren JY; Chung MH; Aimaier RH; Zhang HB; Li QF; Wang ZC
    J Invest Dermatol; 2022 Mar; 142(3 Pt A):613-623.e7. PubMed ID: 34534577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
    Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
    J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
    Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
    Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression.
    Su W; Sin M; Darrow A; Sherman LS
    Glia; 2003 Jun; 42(4):350-8. PubMed ID: 12730955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.
    Kohlmeyer JL; Lingo JJ; Kaemmer CA; Scherer A; Warrier A; Voigt E; Raygoza Garay JA; McGivney GR; Brockman QR; Tang A; Calizo A; Pollard K; Zhang X; Hirbe AC; Pratilas CA; Leidinger M; Breheny P; Chimenti MS; Sieren JC; Monga V; Tanas MR; Meyerholz DK; Darbro BW; Dodd RD; Quelle DE
    Clin Cancer Res; 2023 Sep; 29(17):3484-3497. PubMed ID: 37410426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
    de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
    Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
    Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.